Viewing nowEmpogin 25 mg (Empagliflozin)
Empagliflozin 25mg
Tablet · Prescription medication
Samjin Pharmaceutical Co., Ltd.

MFDS item code 202102109 · Approved 2021.03.05 · Insurance code 647805150
Improvement of glycemic control in adults with type 2 diabetes
This medication is used in conjunction with dietary and exercise regimens to assist adults with Type 2 diabetes in controlling their blood sugar levels. It can be administered as monotherapy, and if blood sugar control is inadequate, it may be used in combination with metformin, pioglitazone, sulfonylureas, insulin, or DPP-4 inhibitors. In particular, for Type 2 diabetes patients with cardiovascular disease, usage should be discussed with a specialist considering both blood sugar control and the impact on the occurrence of cardiovascular events. This medication helps improve overall blood sugar control and assists in diabetes management.
The recommended dose of this medicine is 10 mg once daily, whether used as monotherapy or as add-on combination therapy with other glucose-lowering agents, such as insulin. If 10 mg of this medicine is well tolerated and additional glycemic control is needed, the dose may be increased to 25 mg once daily. When this medicine is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions, 3. Adverse Reactions). This medicine may be taken with or without food. Swallow the tablet whole. If you miss a dose, take it as soon as you remember. Do not take double the dose in one day. No dose adjustment is necessary in patients with mild renal impairment. Treatment with this medicine should not be initiated in patients with an estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73m2 [or CrCl < 60 ml/min]. In patients who tolerate this medicine well and whose glomerular filtration rate remains < 60ml/min/1.73m2 [or CrCl < 60 ml/min], the dose should be adjusted to or maintained at 10 mg once daily. This medicine should be discontinued if the glomerular filtration rate decreases to < 45 ml/min/1.73m2 [or CrCl < 45 ml/min]. Do not use this medicine in patients with end-stage renal disease (ESRD) or those on dialysis, because efficacy is not expected. No dose adjustment is necessary in patients with mild or moderate hepatic impairment. Use of this medicine is not recommended in patients with severe hepatic impairment, as it has not been studied in this population. No dose adjustment based on age is necessary. Renal function and the risk of volume depletion should be considered in patients aged 75 years or older. Initiation of treatment with this medicine is not recommended in patients aged 85 years or older because clinical experience is limited (see Precautions, 4. General Precautions).
This medication should not be used in certain patients. Individuals with allergies to the active substance or other ingredients should not take this medication. Patients with Type 1 diabetes or experiencing diabetic ketoacidosis should also avoid this medication. It is not administered to patients with severely impaired kidney function, those with end-stage kidney disease, or those undergoing dialysis. Additionally, as it contains lactose, patients with lactose intolerance or certain genetic metabolic disorders should not use this medication. Use with caution in patients with mild impairment of kidney function. If kidney function drops below a certain level, the dosage of this medication may need to be adjusted, or treatment should be discontinued. This medication is not effective in patients with end-stage kidney disease or those on dialysis. In heart failure patients with mild to moderate severity, this medication should be used with caution, and it is not recommended for patients with severe heart failure. When used with insulin or insulin secretagogues, there may be an increased risk of hypoglycemia; therefore, dosage adjustments of these medications may be necessary. Possible side effects of this medication include hypoglycemia, genital infections, urinary tract infections, increased urination, reduction in fluid volume, etc. Notably, hypoglycemia may occur more frequently when used in combination with insulin or sulfonylureas. Diabetic ketoacidosis, a serious metabolic acidosis, may rarely occur; if symptoms appear, immediate medical attention is required. Elderly patients or those at risk of fluid loss should be cautious for dehydration or low blood pressure, and this medication may be temporarily discontinued if necessary. Serious side effects such as liver damage or necrotizing fasciitis have also been reported, hence immediate consultation with a healthcare professional is advised if any unusual symptoms arise. Pregnant women are advised against using this medication, and breastfeeding women should also avoid taking it. The safety of this medication in children has not been established; hence, it should not be used in individuals under 18 years of age. No specific toxic reactions from overdose have been reported, but appropriate treatment may be required depending on clinical conditions. This medication may interact with other drugs, so inform your healthcare provider if you are taking any other medications. During treatment, take caution while driving or operating machinery due to the risk of hypoglycemia, particularly when used in combination with insulin. To use this medication safely, regular kidney function tests and monitoring for unusual symptoms are important.
Not everyone experiences these, and they can vary from person to person.
This medication must be stored in a tightly closed container to protect it from air and moisture. Additionally, it should be stored at room temperature, between 1 to 30 degrees Celsius, and not too hot or cold.
Pale yellow, double-convex, oval film-coated tablet
30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowEmpagliflozin 25mg
Tablet · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Boehringer Ingelheim Korea Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Boehringer Ingelheim Korea Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Donggu Bio Pharmaceutical Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Dong Gu Bio Pharmaceutical Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Korea Prime Pharmaceuticals Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Korea Prime Pharmaceutical Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Kips Biopharma Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.